Doug Samuelson - 08 Oct 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)

Role
Chief Financial Officer
Signature
/s/ Doug Samuelson
Issuer symbol
KAPA
Transactions as of
08 Oct 2025
Transactions value $
$0
Form type
4
Filing time
26 Nov 2025, 17:24:13 UTC
Previous filing
25 Nov 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Samuelson Doug Chief Financial Officer C/O KAIROS PHARMA, LTD., 2355 WESTWOOD BLVD, #139, LOS ANGELES /s/ Doug Samuelson 26 Nov 2025 0001943326

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KAPA COMMON STOCK Award $0 +153K +108.77% $0.00 293K 08 Oct 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date.
F2 Consists of (1) 140,367 shares of common stock and (2) 152,672 RSUs which remain subject to vesting.